The nation of Zimbabwe has declined a substantial US health deal valued at $367m (£272m) spanning five years due to Washington's request for sensitive information.
This move became public following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative has since clarified that the US was seeking health data for scientific study and commercial gain but was unwilling to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to secure a agreement acceptable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Context
This development comes after a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost openness and accountability.
Based on statements, 16 African countries have so far signed these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Put simply, our nation would provide the basic resources for medical research without any assurance that the end products would be available to our people if a new pandemic arise."
National Interest and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were upending frameworks already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This system is designed to ensure that when a nation contributes its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome further dialogue with our US partners on how future co-operation could be structured in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
A leading public health body expressed it recognised the government's concerns, but recommended that negotiations must proceed considering much of the country's Aids initiatives were funded by international support.
"In cases where technical issues arise, including those involving data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," it commented.
This impasse underscores the continuing tensions between accepting vital international aid and safeguarding local interests in an increasingly data-driven world.